Minerva Neurosciences Inc
Uždarymo kaina
4.3 0.23
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
4.23
Max
4.5
Pajamos | 158M -125M |
|---|---|
P/E Sektoriaus vid. | 2.462 50.958 |
Pelnas, tenkantis vienai akcijai | -0.36 |
Darbuotojai | 7 |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +141.38% upside |
Kitas uždarbis | 2026-08-12 |
|---|
Rinkos kapitalizacija | 93K 185M |
|---|---|
Ankstesnė atidarymo kaina | 4.07 |
Ankstesnė uždarymo kaina | 4.3 |
Minerva Neurosciences Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
